Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study characterized scalp microbiome changes in seborrheic dermatitis, then tested whether recombinant human thymosin beta-4 gel could treat it better than standard ketoconazole. Scalp swabs were sequenced for the bacterial 16S rRNA V4 region and the fungal ITS1 region on Illumina platforms. Diversity and differential taxa were compared between patients and healthy controls. A randomized intervention then tracked clinical scores and skin barrier parameters from baseline to day 168.
Who was studied?
The study screened 92 people in China. It assigned 21 healthy individuals to placebo and randomized 71 seborrheic dermatitis patients into three arms. The arms received placebo (25 patients), 2 percent ketoconazole lotion (21 patients), or 0.5 mg per mL recombinant human thymosin beta-4 gel (25 patients). Treatment ran four weeks, with follow-up out to 20 weeks after the intervention ended.
What were the most important findings?
Diseased scalps showed greater Malassezia and Staphylococcus abundance and significantly lower fungal and bacterial diversity than healthy controls, at p below 0.001. LEfSe analysis flagged fungal and bacterial genera enriched in patients. Thymosin beta-4 gel significantly cut the Adherent Scalp Flaking Score and erythema area versus placebo, and improvements persisted during follow-up. It outperformed ketoconazole, which lowered flaking but not erythema. Thymosin beta-4 also restored both fungal and bacterial diversity toward healthy levels and reduced two dominant Malassezia species, with the effect lasting up to 20 weeks after stopping.
What are the greatest implications of this study?
The results position recombinant human thymosin beta-4 as a promising, durable treatment for scalp seborrheic dermatitis, addressing both symptoms and microbiome imbalance more effectively than ketoconazole. Its benefit may stem from restoring microbial homeostasis and rebuilding the skin barrier. The authors describe results as preliminary. The trial was single-region with modest arm sizes, and larger studies are needed to confirm the durability and mechanism.